Details for New Drug Application (NDA): 210060
✉ Email this page to a colleague
NDA 210060 describes DEFERASIROX, which is a drug marketed by Alkem Labs Ltd, Amneal, Annora Pharma, Aurobindo Pharma, Cipla, Epic Pharma Llc, MSN, Pharmobedient, Teva Pharms Usa, Actavis Elizabeth, Alembic, Bionpharma, Glenmark Speclt, Sun Pharm, Torrent, Zydus Pharms, Aurobindo Pharma Ltd, Chartwell Rx, Jubilant Generics, Piramal, and Stevens J, and is included in thirty-five NDAs. It is available from twenty suppliers. Additional details are available on the DEFERASIROX profile page.
The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 210060
| Tradename: | DEFERASIROX |
| Applicant: | Alembic |
| Ingredient: | deferasirox |
| Patents: | 0 |
Suppliers and Packaging for NDA: 210060
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DEFERASIROX | deferasirox | TABLET, FOR SUSPENSION;ORAL | 210060 | ANDA | Alembic Pharmaceuticals Limited | 46708-324 | 46708-324-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-324-30) |
| DEFERASIROX | deferasirox | TABLET, FOR SUSPENSION;ORAL | 210060 | ANDA | Alembic Pharmaceuticals Limited | 46708-325 | 46708-325-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-325-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 125MG | ||||
| Approval Date: | Nov 20, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 250MG | ||||
| Approval Date: | Nov 20, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 500MG | ||||
| Approval Date: | Nov 20, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
